Sancuso® (Granisetron transdermal delivery system): A new formulation for chemotherapy-induced nausea and vomiting

P and T

Volumn 33, Issue 10 PART 2, 2008, Pages 2-27

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANISETRON; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; OXALIPLATIN; PLACEBO; SANCUSO; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANTICIPATORY NAUSEA AND VOMITING; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PIGMENTATION CHANGE; APPLICATION SITE PRURITUS; APPLICATION SITE VESICLE; AREA UNDER THE CURVE; ASPIRATION PNEUMONIA; BOERHAAVE SYNDROME; BREAST CANCER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HEALTH CARE COST; HEALTH INSURANCE; HOT FLUSH; HUMAN; MALLORY WEISS SYNDROME; MALNUTRITION; MEGACOLON; METABOLIC DISORDER; MORBIDITY; NASOPHARYNX CARCINOMA; NAUSEA; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; PROPHYLAXIS; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SEX DIFFERENCE; SINGLE DRUG DOSE; SKIN SENSITIZATION; TREATMENT DURATION; VERTIGO; VOMITING;

EID: 55249126884     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Shih YT, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 2007;110(3):678-685.
2. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002;20:4636-4642.
3. American Cancer Society: Cancer Facts & Figures 2008, p 10. Available at: www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf). Accessed May 20, 2008.
4. Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-1117.
5. American Society of Health-System Pharmacists (ASHP). Therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729-764.
6. Burish TG, Tope DM. Psychological techniques for controlling the adverse side effects of cancer chemotherapy: Findings from a decade of research. J Pain Symptom Manage 1992;7(5):287-301.
7. Ritter HL, Gralla RJ, Hall SW, et al. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Cancer Invest 1998;16(2):87-93.
8. Chua DTT, Sham JST, Au GKH, et al. The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: A randomized crossover trial. Br J Clin Pharmacol 1996;41:403-408.
9. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: Clinician and patient perspectives. J Support Oncol 2007;5(7, Suppl 1):5-12.
10. Vanscoy GJ, Fortner B, Smith R, et al. Preventing chemotherapy-induced nausea and vomiting: The economic implications of choosing antiemetics. Community Oncol 2005;2(2):127-132.
11. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Antiemesis. Version 3.2008, February 5, 2008.
12. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology (ASCO) Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol 2006;24(18):2932-2947.
13. Multinational Association of Supportive Care in Cancer (MASCC). Perugia International Cancer Conference VII. Consensus conference on antiemetic therapy. Perugia, 2004 (latest update, 2007).
14. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-2494.
15. Clinical Study Report 392MD/26/C. Strakan Pharmaceuticals Ltd. June 2007.
16. Kytril® (granisetron HCl) tablets and oral solution, package insert. Nutley, NJ: Roche Laboratories, Inc.; November 2005.
17. Kytril (granisetron HCl) injection, package insert. Nutley, NJ: Roche Laboratories, Inc.; November 2005.
18. Clinical Study Report 392MD/15/C. Strakan Pharmaceuticals Ltd. May 2007.
19. Wilkosz MF, Bogner RH. Transdermal drug delivery. Part 1: Current status. Volume 28:04. Posted April 15, 2005. Available at: www.uspharmacist.com/index. asp?show=article&page=8_1061.htm.
20. Clinical Study Report 392MD/11/C. Strakan Pharmaceuticals Ltd., September 2005.
21. Clinical Study Report 392MD/4/C. Strakan Pharmaceuticals Ltd., October 2003.
22. Clinical Study Report 392MD/8/C. Strakan Pharmaceuticals Ltd., July 2006.
23. Integrated Summary of Efficacy 5.3.5.3.1. Strakan Pharmaceuticals Ltd.
24. Integrated Summary of Safety 5.3.5.3.2. Strakan Pharmaceuticals Ltd.